Numinus Wellness Inc.

Numinus Wellness Inc.

Cedar Clinical Research selected as clinical research site for Beckley Psytech’s Phase 2b Study

VANCOUVER, BC, Dec. 15, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is proud to announce that its research site, Cedar Clinical Research (CCR), has bee... Read More...

Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD

VANCOUVER, BC, Dec. 13, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, congratulates the Multidisciplinary Association of Psychedelics Studies ("MAPS" or "MAPS PBC") for its submission of a new drug a... Read More...

Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations

The Company is ceasing operating activities at Numinus Bioscience – its non-revenue producing research lab, and is consolidating clinic operations in certain regions to enhance company performance and improve the overall client experience. Collectively, these activities are expected to save nearly C$1 million of annualized cash expenses,... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023

VANCOUVER, BC, Aug. 9, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Nikhil Handa, CFO, will participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023, at... Read More...

Numinus Appoints New Chief Financial Officer

VANCOUVER, BC, June 14, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the appointment of Nikhil Handa as Chief Financial Officer, effective June 15, 2023, following a thorough executi... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023

VANCOUVER, BC, June 2, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, June... Read More...

Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

First Numinus Network™ partner enters into agreement Recent cost containment initiatives have resulted in approximately $4.2 million of annualized savings, extending cash runway Well positioned to provide psychedelic-assisted therapy insurance reimbursement, as a result of recent US insurance payor code approval MDMA-assisted therapy e... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023

VANCOUVER, BC, April 17, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, Ap... Read More...

Numinus Launches the Practitioner Certification Pathway

VANCOUVER, BC, March 27, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched the Numinus Certification Pathway – a collection of psychedelic-assisted therapy ("PAT") tr... Read More...

Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023

VANCOUVER, BC, March 22, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Sequire Cannabis & Psychedelics Conference to be held virtually on Wednesday... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023

VANCOUVER, BC, Feb. 24, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Dr. Paul Thielking, Chief Science Officer of Numinus, will participate in a Water Tower Research Fireside Ch... Read More...

Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea

Clinical trial will be the first to test whole Psilocybe mushrooms for safety and efficacy in a clinical setting; study is expected to provide important data to support increased access to psilocybin-assisted therapy. Clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy and will ... Read More...

Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research

New clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy. Clinical trial dosing will use Numinus Bioscience's Psilocybin Tea, EnfiniTea – one of the first Phase 1 clinical trials that will report on whole Psilocybe mushroom safety. VANCOUVER, BC, Dec. 8, 2022 - Numinus Wellness ... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022

VANCOUVER, BC, Nov. 22, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Thursday, Dece... Read More...

Miami on November 3-5, 2022

 VANCOUVER, BC, Oct. 31, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Cent... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022

VANCOUVER, BC, Oct. 7, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a Water Tower Research Fireside Chat on Thur... Read More...

Numinus to Participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022

VANCOUVER, BC, Sept. 29, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) ( OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in ... Read More...

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Treatment will be offered at the Neurology Centre of Toronto in Forest Hill VANCOUVER, BC, Sept. 19, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) ( OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its Toronto clinic, the Neurol... Read More...

Numinus provides update on acquisition integration and announces new client financing options

US clinics acquired from Novamind demonstrating continued growth Physical rebranding of clinics is underway Announcing new client financing options in Canada VANCOUVER, BC, Sept. 13, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) ( OTCQX: NUMIF) is pleased to provide an update on the integration of the Novamind acqu... Read More...

Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

VANCOUVER, BC, Aug. 31, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte ... Read More...

Numinus Unveils New Logo and Brand Identity

New branding unifies Numinus' presence across North America Rebranding will be accomplished in phases and completed by end of 2022 VANCOUVER, BC, June 27, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce the launch of a new visual brand identity that will be applied to all Company ... Read More...

Numinus to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022

VANCOUVER, BC, June 21, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 1st Annual Mental Health Conference to be held at the Lotte New Yor... Read More...

Numinus announces shareholder approval of resolution in connection with the proposed acquisition of Novamind

Novamind shareholders, at a separate meeting held today, have also approved the transaction Transaction expected to be completed on or about June 10, 2022 VANCOUVER, BC, June 8, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce shareholders have approved the Company's resolution to... Read More...

Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment

Approval Marks Numinus' First use of Psilocybin-Assisted Therapy Treatment Outside of Clinical Trials VANCOUVER, BC, May 16, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Health Ca... Read More...

Numinus to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022

VANCOUVER, BC, May 11, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a fireside chat hosted by Patrick Trucchio, H.... Read More...

Numinus Mails Materials for Special Meeting of Shareholders and Announces Interim Court Order for Plan of Arrangement

Shareholders are encouraged to vote their common shares prior to the proxy deadline of June 6, 2022 at 11:00 a.m. PT VANCOUVER, BC, May 10, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) today announces the mailing of its management information circular (the "Circular") and related materials for the spe... Read More...